Project Grant R21OD035572
Award Date
9/1/24
Completion Date
7/31/26
Dollars Obligated
$364K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
Aggregate Financial Assistance Data
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30329, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $800,389.00 to Emory University to evaluate the safety and therapeutic potential of a novel HIV treatment strategy. The goal is to develop a combination therapy using soluble IL-15/IL-15RA-FC and TGF-beta pathway blockade, along with therapeutic vaccination, to enhance and restore anti-viral immunity and lead to sustained viral...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,332,155 to Emory University to conduct research focused on developing immunotherapies to cure HIV in SHIV-infected infant macaques. The key objectives are to evaluate strategies that leverage broadly neutralizing antibodies (bNAbs) in combination with virus reactivation, innate immune stimulation, and attachment...
This $812,810 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Emory University to generate highly differentiated natural killer (NK) cells and evaluate their synergistic effects with broadly neutralizing antibodies in reducing the SIV reservoir and establishing viral control in the absence of antiretroviral therapy (ART). The key objectives are to: 1) define...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $617,376 to Emory University to conduct research on the activation and maturation of the HIV-1 virus. The key objectives are to: 1) Measure the timing of protease (PR) activation relative to HIV-1 budding from the host cell, 2) Assess the rate and extent of PR substrate cleavage and correlate this with formation of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $862,398 to the Fred Hutchinson Cancer Center in Seattle, WA over a 5-year period starting on August 1, 2025. The goal of this project is to develop novel chimeric antigen receptor (CAR) T-cell therapies that can selectively target and deplete the PD-1+ HIV/SIV reservoir in non-human primate models. The research aims to advance understanding of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616 to Emory University to develop virus-like particles (VLPs) for use in HIV-1 cure strategies. The key products and services to be delivered under this 18-month project include: Using VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, as part of a "shock and kill" strategy to...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $183,602 to The University of North Texas Health Science Center at Fort Worth to support research on engineering a simian-compatible version of HIV-1. The goal is to construct an "HSIV" virus, which has an HIV-1 backbone with minimal SIV gene fragments, to enable more effective studies of AIDS pathogenesis...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $824,331 to the Trustees of Boston College to conduct research on "Understanding Formation and Dynamics of the SIV Reservoir." The project aims to investigate the early establishment and persistence of viral reservoirs in HIV/SIV infection, with a focus on the potential role of naive CD4+ T cells in...
The National Institutes of Health (NIH) awarded Emory University a $8,000,000 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to expand the specific-pathogen-free (SPF) rhesus macaque breeding colony at the Emory National Primate Research Center. The new animal housing will consist of 16 indoor/outdoor run areas and support space to facilitate targeted genetic breeding for SIV/AIDS research. This expansion is intended to provide additional animals to support the $23.8M...